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Abstract
Monkeypox virus (MPXV) infection in humans results in clinical symptoms very similar to ordinary smallpox. Aerosol is a
route of secondary transmission for monkeypox, and a primary route of smallpox transmission in humans. Therefore, an
animal model for aerosol exposure to MPXV is needed to test medical countermeasures. To characterize the pathogenesis in
cynomolgus macaques (Macaca fascicularis), groups of macaques were exposed to four different doses of aerosolized
MPXV. Blood was collected the day before, and every other day after exposure and assessed for complete blood count
(CBC), clinical chemistry analysis, and quantitative PCR. Macaques showed mild anorexia, depression, and fever on day 6
post-exposure. Lymphadenopathy, which differentiates monkeypox from smallpox, was observed in exposed macaques
around day 6 post-exposure. CBC and clinical chemistries showed abnormalities similar to human monkeypox cases. Whole
blood and throat swab viral loads peaked around day 10, and in survivors, gradually decreased until day 28 post-exposure.
Survival was not dose dependent. As such, doses of 4610
4 PFU, 1610
5 PFU, or 1610
6 PFU resulted in lethality for 70% of
the animals, whereas a dose of 4610
5 PFU resulted in 85% lethality. Overall, cynomolgus macaques exposed to aerosolized
MPXV develop a clinical disease that resembles that of human monkeypox. These findings provide a strong foundation for
the use of aerosolized MPXV exposure of cynomolgus macaques as an animal model to test medical countermeasures
against orthopoxviruses.
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Introduction
After a centuries-long battle, humans defeated smallpox and it
was declared eradicated in 1980. Smallpox vaccination was then
discontinued, leaving most of today’s population vulnerable to
Variola virus (VARV) (smallpox agent). MPXV is a close relative of
VARV, sharing 96.3% identity within the central region of the
genome encoding essential genes, and 84.5% identity overall [1].
MPXV causes a disease in humans that is clinically indistinguish-
able from ordinary smallpox, with the exception of lymphade-
nopathy [1,2,3]. Vaccinia-based vaccines, used for worldwide
eradication of VARV, are protective against MPXV challenge in
animal models and are also presumed to protect humans from
monkeypox [4,5,6,7,8,9,10,11,12]. The similarity of monkeypox to
smallpox, and the growing lack of immunity in the population
have caused concerns that these viruses might be used as biological
weapons. This has prompted scientists to develop new medical
countermeasures against poxviruses. Because evaluation of
medical countermeasures against poxvirus infection in humans is
not ethical or feasible, showing efficacy in an animal model that
emulates human disease is required by the ‘‘Animal Rule’’ of the
US Food and Drug and Administration (FDA) [13]. Non-human
primates (NHPs) are closely related to humans and are often the
most accurate model system for the study of human disease
processes. Therefore it is important to develop a model of MPXV
infection in NHPs, using the most relevant route, in order to fully
evaluate pathogenesis as well as the capabilities of vaccines and
therapeutics.
The use of VARV in research is highly restricted; therefore,
viruses from other members of the orthopoxvirus family are used
to develop animal models to test medical countermeasures against
poxviruses. There are few orthopoxvirus animal disease models
that simulate the pathophysiology and unique clinical progression
of smallpox and monkeypox in humans. The current models
utilize a wide range of orthopoxviruses, animal species, and
challenge routes. The current animal models include: vaccinia
virus in mice by intranasal (i.n.), intraperitoneal (i.p.) or
intravenous (i.v.) routes, cowpox virus in mice and marmosets by
the i.n. route, ectromelia in mice by aerosol and i.n. routes,
vaccinia virus or rabbitpox virus in rabbits by intradermal (i.d.) or
aerosol routes, monkeypox virus in dormice, prairie dogs or
ground squirrels by i.n. or i.p. routes, monkeypox virus in monkeys
by intratracheal (i.t.) and i.v. routes, and VARV in monkeys by the
i.v. route +/2 aerosol route [12,14,15,16,17,18,19,20,21].
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route [22]. Furthermore, an intentional release of VARV or
MPXV would likely be in aerosol form. Therefore, the aerosol
route of transmission should be one of the features of an animal
model which will be used as a model for human smallpox and
monkeypox infection. No single model recapitulates all the aspects
of smallpox or monkeypox in humans, yet the most relevant
models, MPXV or VARV infection of NHPs by the aerosol route,
have not been fully characterized [23,24,25]. Studies of aerosol
MPXV infection models require biosafety level 3 (BSL-3)
laboratories and class III biosafety cabinets containing specialized
aerosol equipment. The single published study of aerosolized
MPXV infection of cynomolgus macaques gave a detailed account
of the pathology induced by the virus in various tissues, but did not
address a number of facets of the clinical disease progression
[23,25]. We present that cynomolgus macaques exposed to
aerosolized MPXV show many characteristics of monkeypox
and smallpox in humans and is thus an appropriate model for
orthopoxvirus pathogenesis, vaccine and therapeutic studies.
Materials and Methods
Animals and Ethical Statement
Healthy, adult cynomolgus macaques (Macaca fascicularis) of both
sexes were obtained from the United States Army Medical
Research Institute of Infectious Diseases (USAMRIID) NHP
colony. All MPXV exposed animals were handled in a BSL-3
containment laboratory at USAMRIID. Research was conducted
in compliance with the Animal Welfare Act and other federal
statutes and regulations relating to animals and experiments
involving animals, and adhered principles stated in the Guide for
the Care and Use of Laboratory Animals, National Research
Council, 1996. The facility where this research was conducted
(USAMRIID) is fully accredited by the Association for the
Assessment and Accreditation of Laboratory Animal Care
International. Research was conducted under a protocol approved
by the Institutional Animal Care and Use Committee (IACUC) at
USAMRIID. All animals were examined and evaluated twice per
day by study personnel. Early endpoint criteria, as specified by the
score parameters within the ‘‘Post-exposure observations’’ section
of these methods, were used to determine when animals should be
humanely euthanized.
Virus
MPXV (Zaire V79-I-005 strain) was provided by the Biodefense
and Emerging Infections Research Resources Repository (BEI
Resources)/ATCC. Virus was diluted in Eagle’s Minimum
Essential Medium (EMEM) with 2% fetal bovine serum (FBS) to
achieve desired doses (Table 1).
Plaque Assay
MPXV was titrated in complete Eagles Minimum Essential
Media containing non-essential amino acids (EMEM/NEAA
media) supplemented with 2% FBS, penicillin (8 IU/mL),
streptomycin (80 mg/mL), gentamicin (0.02 mg/mL) and fungi-
zone (0.1 U/mL) warmed to 37uC. Plaque assays were carried out
on Vero E6 cells at approximately 95% confluency. One
hundred mL of each dilution was added to each well of a six-
well plate. Plates were incubated for 1 hour in at 37uC, rocking
plates every 10–15 minutes. After one hour, two mL of complete
media were added to each well and incubated for 4 days at 37uC.
On day 4, media was removed from the plates and 500 mL 10%
crystal violet was added to each well for approximately 10–20
minutes. Once cells were stained, plates were rinsed by submersion
in cold water and placed upside down to dry overnight. Plaques
were counted the following day.
Aerosol exposures
Each macaque was anesthetized by intramuscular (i.m.)
injection of tiletamine/zolazepam (6 mg/kg), and whole body
plethysmography (Buxco Research Systems, Wilmington, NC) was
performed to determine the respiratory minute volume as
previously described [26]. Subsequently, each macaque was
exposed to MPXV in a head-only chamber contained in a class
III biological safety cabinet located inside a BSL-3 suite. The
Automated Bioaerosol Exposure System (ABES) served as the
control platform for the aerosol exposures [27]. Aerosols were
generated with a three-jet collison nebulizer (BGI, Inc., Waltham,
MA), and integrated air samples were collected throughout the
exposure with an all glass impinger (AGI).
To improve the precision of presented aerosol doses, the ABES
was programmed to dynamically calculate the exposure time
based on the minute volume measurement for each macaque, the
flow to volume ratio of the exposure chamber, the starting MPXV
concentration in the collison nebulizer, and the historical spray
factor for MPXV virus. For each individual exposure, these
parameters were entered into the ABES, and the ABES
determined the time required to reach the required dose. ABES
calculations were based on a dynamic model that estimates
chamber aerosol concentration based on the flow to volume ratio
in the chamber.
After exposure, AGI samples were analyzed by performing a
plaque assay. An inhaled MPXV dose was calculated for each
macaque based on the plaque assay and the minute volume
measurement.
Telemetry
A radiotelemetry device (Data Sciences International (DSI), St.
Paul, MN), used to monitor temperature and activity, was
surgically implanted into macaques at least 14 days before aerosol
exposure. Body temperatures were recorded every 15 min by the
DataQuest A.R.T.4.1 system (DSI). Pre-exposure temperature
data were used to create a baseline to fit an autoregressive
integrated moving average (ARIMA) model. Temperature eleva-
tions exceeding three standard deviations over the baseline were
used to compute fever duration, hours, and average elevation.
Post-exposure observations
Macaques were observed at least twice a day after aerosol
exposure. Macaques were scored for clinical signs of disease prior
to, and while under anesthesia. The scoring parameters were:
responsiveness and appearance (0: active; 2: depression, mild
unresponsiveness; 3: head down, hunched; 4: moderate unrespon-
siveness; 5: severe unresponsiveness), dyspnea (0: normal breath-
ing; 2: mildly labored; 3: labored; 5: agonal breathing),
dehydration (0: not present; 1: mild; 2: moderate; 3: severe),
anorexia (0: eating; 1: no biscuits for 1 day but eats enrichment; 2:
no biscuits for 2 days or not eating enrichment), rash (0: none; 1:
slight; 2: moderate; 3: severe), cough (0: none; 1:#2 coughs/
5 min; 2: 3–10 coughs/5 min; 3: $10 coughs/5 min), nasal
discharge (0: none; 1: mild; 2: moderate; 3: severe), urine (0:
normal; 3: none), stool (0: normal; 1: loose stool, 2: liquid stool or
none), and fever (0: no change, 1: baseline +1uC; 2: baseline +2uC
or higher; 3: baseline – 2uC). Macaques were also evaluated for
changes in weight (0: no change; 1: baseline-10–15%; 2: baseline –
15%; 3: baseline – 20%) and the presence of lymphadenopathy (0:
,3 mm; 1: 3–9 mm; 2: .10–19 mm; 3: .20 mm). The early
endpoint criteria for humane euthanasia, indicative of very poor
Aerosolized Monkeypox Virus
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score), and/or a sudden drop of .3uC from baseline body
temperature.
Clinical laboratory evaluations
Beginning one day before, and every other day on days 2–28
after exposure, blood samples were collected from the femoral vein
of macaques anesthetized with tiletamine/zolazepam (3 mg/kg;
IM). Samples collected one day prior to exposure served as a
normal reference baseline for each animal. CBCs and blood
chemistries were analyzed with Beckman Coulter hematology and
VITROS 250 chemistry analyzers.
DNA extraction and real-time polymerase chain reaction
(RT-PCR)
Tissue samples were collected from all major organ systems and
frozen. One gram of each tissue was pulverized with 1 mL EMEM
plus 2.5 mL penicillin (20,000 IU/mL)/streptomycin (200,000
mg/mL) solution using a handheld Omni International (Kenne-
saw, GA) tissue homogenizer with a single use disposable plastic
tissue grinding tip. Blood and throat swabs were collected from
macaques every other day after exposure to aerosolized MPXV.
Viral DNA was isolated from 200 ml of tissue suspension, 100 mlo f
blood, or 100 ml of throat swab media with a BioRobot M48
(Qiagen, Valencia, CA) according to the manufacturer’s instruc-
tions. Real-time PCR was performed with the LightCycler (Roche,
Indianapolis, IN) using a pan-orthopoxvirus hemagglutinin assay
(HA), as previously described [28].
Necropsy
A necropsy was performed under BSL-3 conditions on animals
that were humanely euthanized when moribund or, if they
survived, at the end of the study. Tissue samples from all major
organ systems (respiratory, gastrointestinal, genitourinary, lym-
phoid, neurologic, endocrine, skin and mucous membranes) were
collected from each animal for histopathological and immunohis-
tochemical examination and were immersion-fixed in 10%
neutral-buffered formalin.
Histology and immunohistochemistry
Formalin-fixed tissues for histologic examination were trimmed,
processed, and embedded in paraffin according to established
protocols [29]. Histology sections were cut at 5 mm, mounted on
glass slides, and stained with hematoxylin and eosin (H&E).
Immunohistochemical staining was performed on replicate tissues
sections using an EnVision + kit (DAKO, Carpinteria, CA).
Normal splenic tissue served as the negative control; the positive
control was spleen from a known MPXV infected NHP; and
normal rabbit serum was used as the negative serum control.
Briefly, sections were deparaffinized in xyless, rehydrated in
graded ethanol, and endogenous peroxidase activity was quenched
in a 0.3% hydrogen peroxide/methanol solution for 30 min at
room temperature. Slides were washed in phosphate buffered
saline (PBS) then sections were incubated in the primary antibody,
a rabbit polyclonal antibody against vaccinia virus, diluted 1:3500
for 60 minutes at room temperature. Sections were washed in PBS
and incubated for 30 min with EnVision + rabbit secondary
reagent (horseradish peroxidase-labeled polymer) at room tem-
perature. Peroxidase activity was developed with 3, 39-diamino-
benzidine (DAB), counterstained with hematoxylin, dehydrated,
cleared with xyless, then coverslipped.
Digital Microscopy Image Analysis
Digital microscopy was performed using an Automated Cellular
Imaging System (ACISH II, Dako, Carpenteria, CA) which uses
proprietary software to allow for color detection and analysis of
morphometric features. This system consists of an automated
robotic bright-field microscope module, a computer, and a
Microsoft Windows NT based software interface. The robotic
microscope module scanned the immunohistochemically stained
slides and the digitized images were displayed on the computer
monitor. The pathologist reviewed the images and an ACIS-
assisted score was generated by the system software as a means of
quantitating the vaccinia virus staining in the tissue. Technical
details about the ACIS digital microscopy system are presented
elsewhere [30].
Statistical analysis
Repeated measures analysis of variance (RM-ANOVA) was
used to compare temperature, weight, white blood cells (WBC),
blood chemistries, and viral genomes among groups until day 10,
since after that time, the 1610
5 PFU group had two survivors and
the other groups had one survivor each. Group comparisons for
time-to-death were calculated by t-tests with step-down Bonferrini
correction. RM-ANOVA of log10 transformed data was used for
comparison of viral genome load in blood and throat swabs
between groups over time. T-tests of log10 transformed data were
performed for viral genome load from tissues between groups.
Analyses were two-tailed and conducted using SAS v9.1.3. Results
were significant at P,0.05.
Table 1. Summary of inhaled doses, fever, and disease outcome in cynomolgus macaques exposed to aerosolized MPXV.
Groups (PFU)
Inhaled dose
(PFU) (average)
Fever onset
(study day)
a
Fever duration
(hours)
b Fever hours
c DT max, uC
d
Average elevation
in temperature
(uC)
e MTD (days)
f
Survivors/
total
4610
4 4.3610
4 4.7 105.3 215.3 2.5 1.9 10.0 1/3
1610
5 1.4610
5 3.8 121.5 244.7 3.3 1.9 9.0 2/6
4610
5 4.4610
5 2.8 120.8 266.7 3.4 2.1 9.6 1/6
1610
6 1.1610
6 4.3 123.6 278.1 3.5 2.3 8.5 1/3
aDefined as the first day with .8 h of significant temperature elevation (as determined by ARIMA modeling).
bCalculated as the number of days (converted to hours) with 12 or more h of significant temperature elevation.
cCalculated as the sum of the significant temperature elevations.
dThe maximum change in temperature.
eCalculated by dividing fever hours by fever duration in hours.
fMean time-to-death.
doi:10.1371/journal.pone.0012880.t001
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Clinical signs and survival
In this study, four groups of cynomolgus macaques were
exposed to increasing doses of aerosolized MPXV, with a particle
size of 1–3 mm (Table 1). As little as 200 pfu MPXV delivered by
the aerosol route was sufficient to cause non-lethal disease,
including lesions (data not shown). The doses were 4610
4 PFU
(n=3), 1610
5 PFU (n=6), 4610
5 PFU (n=6), and 1610
6 PFU
(n=3), chosen based on optimization of the dose range required
for consistent infection (data not shown). The calculated inhaled
doses were very close to target doses for each group (Table 1).
Animals started to show clinical signs of disease, including
decreased appetite and activity, by day 3. Lymphadenopathy of
inguinal and axillary nodes was observed starting 6–7 days post-
exposure. By 6–8 days post-exposure, macules began to form in all
animals and macaques were also inactive, somnolent, and
exhibited depressed posture. The clinical score of all macaques
peaked on day 10 post-exposure and there were no significant
differences among groups (Figure 1A). Lesions progressed to
papules by day 10 and evolved to vesicular and pustular stages by
12–14 days post-exposure. Surviving macaques were active, eating
well, had scabbed lesions and had greatly reduced clinical scores
by day 20. Of note, the number of lesions was not dose dependent
and varied widely with 60–730 lesions among survivors, and 10–
180 lesions among 11 of 13 non-survivors. Two non-survivors had
too many lesions to count (.2000).
Survival was not dose dependent, with doses of 4610
4 PFU,
1610
5 PFU, and 1610
6 PFU resulting in 33% survival and
4610
5 PFU resulting in approximately 17% survival (Fig. 1B).
Although death was delayed in the lowest dose group, there were
no significant differences in the mean time-to-death (MTD)
(Table 1). Most of the macaques met criteria for euthanasia on
days 8–11. Surviving macaques had less severe disease, except for
one macaque in the highest dose group, which had severe disease
but never met the score criteria for euthanasia.
Body temperature and weight changes
Fever was delayed until day 5 in the lowest dose group compared
to day 4 for the other groups (Table 1 and Figure 1C). However,
differences were not significant between the groups regarding onset,
duration, or magnitude of fever. By day 5 post-exposure, all groups
had an average elevation in body temperature of 2uC. The lowest
dose group had the shortest fever duration,whereasthe highestdose
group had the longest. Similarly, the lowest dose group had the
fewest fever hours, calculated as the sum of significant temperature
elevations, and the highest dose group had the most.
Even though there were no significant weight changes over time
among groups after MPXV exposure, weight was significantly
different between survivors and non-survivors regardless of dose
Figure 1. Clinical disease scores, survival, temperature and weight. A) Changes in average clinical scores and B) percent survival of
macaques exposed to different doses of aerosolized MPXV. C) Average body temperature of macaques exposed to different doses of aerosolized
MPXV. The temperature data was collected every 15 min from implanted telemetry devices. The dashed line indicates the average baseline body
temperature; n: number of animals. D) Changes in average body weight of survivors and non-survivors exposed to aerosolized MPXV. n: number of
animals.
doi:10.1371/journal.pone.0012880.g001
Aerosolized Monkeypox Virus
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12880(P,0.0001) (Figure 1D). Survivors were approximately 20%
heavier than non-survivors.
Clinical laboratory evaluation
In contrast to a previous report on aerosol infection of
cynomolgus macaques with MPXV which reported no significant
changes in CBCs or blood chemistries after infection, a number of
changes were observed in this study [25]. WBCs decreased slightly
on day 2 and increased after day 4 in all groups except for the
lowest dose group (P=0.0011) (Fig. 2A). All three dosage groups
had data points that were above the normal reference range on
certain days. Granulocytes decreased on day 2, followed by a
Figure 2. Average number of leukocytes and platelets in macaques after exposed to aerosolized MPXV. The dotted lines indicate the
normal reference range; n: number of animals. Graphs are shown for A) total white blood cells (WBC), B) percentage of granulocytes (GR),
C) percentage of lymphocytes (LY), D) platelets (PLT) for all MPXV dosage groups, and survivors versus non-survivors (right).
doi:10.1371/journal.pone.0012880.g002
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peripheral lymphocytes increased on day 2 followed by a sharp
decrease on day 4 post-exposure (Fig. 2C). There were no
significant differences on days 21–10 between survivors and non-
survivors regarding changes in WBC, granulocyte, or lymphocyte
values.
Platelets decreased steadily from day 2 to day 6. Platelets were
lowest on day 6 post-exposure, which was significantly lower than
day 21( P,0.0001), and increased after day 6 but stayed within
the normal range (Fig. 2D). Interestingly, non-survivors had
significantly higher levels of platelets than survivors on days 21t o
10 (P=0.0011).
Figure 3. Serum chemistries in macaques exposed to aerosolized MPXV. The dotted lines indicate the normal reference range; n: number of
animals. Graphs show average A) total protein, B) albumin, C) lactate dehydrogenase (LDH), D) C-reactive protein, E) aspartate transaminase (AST),
F) and alanine transaminase (ALT), G) urea nitrogen.
doi:10.1371/journal.pone.0012880.g003
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before exposure and every other day on days 2–28. Considerable
changes were observed in total protein, albumin, lactate
dehydrogenase (LDH), and C-reactive protein values in all
macaques over time, but the changes were similar for all groups
on days 21 to 10 for total protein, albumin, and C-reactive
protein (Fig. 3A-D). There were also no significant differences in
serum chemistries on days 21–10 between survivors and non-
survivors (data not shown). In contrast, there were significant
differences in LDH levels between groups after MPXV infection
(P=0.0002). Alanine and aspartate amino transaminases (ALT
and AST) stayed within normal ranges and groups did not differ
statistically (Fig. 3E-F). Levels of blood urea nitrogen (BUN) did
not differ significantly among groups (Fig. 3G). However,
compared to day -1, BUN was significantly lower for all animals
on day 6 (P=0.0003), and higher for animals surviving until day
10 (P=0.0091).
Viral load
Viral loads in whole blood and throat swab samples from
exposed macaques were assessed using real-time PCR (Figure 4A-
B). Viral genomes in both whole blood and throat swabs were
detected as early as day 4 post-exposure. The viral load peaked on
day 10 for both blood and throat swab samples and gradually
decreased thereafter. There were no group-wise differences
between blood or throat swab viral load on days 1–10, but the
viral levels in whole blood and throat swabs were higher in non-
survivors than survivors (blood P=0.0445, throat swabs
P,0.0001).
DNA was isolated for real-time PCR from selected tissues of
macaques euthanized during acute disease and in those that were
euthanized at the end of the study. As expected, lung tissue and
pock lesions had the highest viral load for most exposure groups,
reaching 10
10 genomes/g (Fig. 5A). Spleen, gonads, axillary lymph
nodes, and inguinal lymph nodes also showed high viral loads in
all groups. Viral loads were much higher in the tissues from
macaques euthanized during acute illness, in contrast to those that
were convalescing (Fig. 5B). Virus persisted in gonads and kidneys
but was reduced in other organs of survivors 28 days post-
exposure.
Pathology
Gross and histopathologic features of animals euthanized during
acute disease (days 8–11 post-exposure) were similar to those
previously reported for aerosolized MPXV [25]. Key histopath-
ologic findings are presented in Table 2. The cause of death was
attributed to primary fibrinonecrotic bronchopneumonia. Necro-
tizing lesions were also present in the skin, gastrointestinal tract
(esophagus, stomach, duodenum, colon), lymphoid organs (tonsil,
spleen, thymus, gut-associated lymphoid tissue, lymph nodes),
Figure 4. Average number of MPXV viral genomes in whole blood and throat swabs. The average number of MPXV viral genomes in
A) whole blood, and B) throat swabs from different MPXV dosage groups, and survivors versus non-survivors (right). The X-axis is at the limit of
detection =5000 genomes/ml; n: number of animals.
doi:10.1371/journal.pone.0012880.g004
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Additional necrotizing lesions were observed rarely in the prostate
gland, uterus, skeletal muscle, urinary bladder, bone marrow, and
conjunctiva. MPXV-associated lesions were not observed in the
liver. There were mild variations in severity of lesions among the
different groups, although these differences were not dose-
dependent.
Survivors had a variety of chronic lesions, including discrete,
nodular to coalescing areas of necrosis and inflammation in the
lung and mediastinal lymph nodes, chronic inflammation centered
on bronchi and vessels, type II pneumocyte hyperplasia, pleural
and interstitial fibrosis, and fibrous pleural adhesions. Other
lesions included lymphoid hyperplasia and plasmacytosis, and
chronic periadnexal and perivascular dermatitis.
Positive orthopoxvirus immunoreactivity was associated with
necrotizing lesions in animals that died during acute disease. In the
lungs, this was predominantly concentrated around bronchi and
bronchioles (Fig. 6A-D). No poxvirus immunoreactivity was
observed in normal uninfected NHP splenic tissue which served
as a negative control (data not shown). The percentage of
orthopoxviral antigen in lung sections of non-survivors increased
with increasing dosage of virus, but the differences were not
significant (Fig. 6E). In animals that survived, non cell-associated
poxvirus antigen was detected in the center of discrete areas of
necrosis in the lung (3/5 animals) and mediastinal lymph node (1/
5 animals) - these findings were not dose-dependent.
Discussion
Different routes of poxvirus exposure can lead to variations in
disease course in both humans and monkeys [31,32]. Many studies
used i.v. delivery of MPXV as a model for smallpox and to test
vaccines and countermeasures [33]. However, aerosol delivery of
MPXV most closely mimics the route of natural transmission of
smallpox among humans, which is by the respiratory route [22].
The pathogenesis of aerosol MPXV infection is comparable to
smallpox because the infection is initiated in the respiratory
mucosa followed by spread to local lymph nodes before primary
Figure 5. Viral load in tissues. A) Tissue viral load of macaques exposed to different doses of aerosolized MXPV and euthanized during the acute
phase of disease (survivors are not included). B) Tissue viral load in survivors and non-survivors. The X-axis is at the limit of
detection=5000 genomes/g; n: number of animals.
doi:10.1371/journal.pone.0012880.g005
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that the initial infection of respiratory tissue, incubation, and
prodromal phases are bypassed with the direct initiation of
viremia. The same phenomenon has occurred in human MPXV
infections initiated by scratch or bite versus those presumed to
have occurred by respiratory exposure [31]. This is an important
caveat when the utility of these models is meant to test possible
vaccines and treatments in which the efficacy may depend on
protecting the respiratory mucosa and targeting subsequent early
stages of the infection, which are not represented in the i.v.
challenge model.
A marmoset (Callithrix jacchus) model of intranasal calpox, a
strain of cowpox virus, was recently evaluated [14]. Advantages of
this model include the lower lethal dose required and the relative
ease of husbandry of marmosets compared to larger species of
NHPs. However, there are several disadvantages to the intranasal
marmoset calpox model. First, the intranasal route is less
physiologically relevant to a naturally occurring poxvirus infection,
despite the relative technical ease at which intranasal challenge
can be accomplished compared to aerosol challenge. Additionally,
the clinical disease course was less similar to that of MPXV or
VARV infection of humans, due to the appearance of very few
pox lesions and the appearance of observable clinical disease of
short duration just prior to death. Finally, perhaps because of the
small size of the marmosets, blood was not drawn with great
frequency and serum chemistries and CBCs were not performed,
thus leaving many features of the clinical disease course
unexplored.
Table 2. Key histopathologic lesions in cynomolgus macaques exposed to aerosolized MPXV.
Tissue 4610
4 PFU 1610
5 PFU 4610
5 PFU 1610
6 PFU
Histopathologic Findings n % n % n % n %
lung
bronchopneumonia,
fibrinonecrotic 2/3 66 4/6 66 5/6 83 2/3 66
pleuritis, necrotizing 3/3 100 4/6 66 3/6 50 2/3 66
discrete foci of necrosis
/inflammation * 1/3 33 0 0 1/6 16 0 0
perivascular/peribronchial
inflammation* 0 0 2/6 33 1/6 16 1/3 33
spleen
splenitis, necrotizing 1/3 33 2/6 33 4/6 66 2/3 66
lymphoid depletion 2/3 66 3/6 50 3/6 50 2/3 66
lymphoid hyperplasia* 0 0 0 0 0 0 1/3 33
mandibular lymph node
lymphadenitis, necrotizing 1/3 33 2/6 33 5/6 83 2/3 66
lymphoid depletion 0 0 2/6 33 3/6 50 1/3 33
lymphoid hyperplasia* 1/3 33 2/6 33 2/6 33 1/3 33
mesenteric lymph node
lymphadenitis, necrotizing 0 0 0 0 0 0 1/3 33
lymphoid depletion 0 0 0 0 1/6 16 2/3 66
lymphoid hyperplasia* 0 0 2/6 33 1/6 16 0 0
axillary lymph node
lymphadenitis, necrotizing 0 0 3/6 50 3/6 50 2/3 66
lymphoid depletion 0 0 2/6 33 0 0 2/3 66
lymphoid hyperplasia* 1/3 33 2/6 33 2/6 33 1/3 33
inguinal lymph node
lymphadenitis, necrotizing 0 0 1/6 16 2/6 33 2/3 66
lymphoid depletion 0 0 0 0 0 0 2/3 66
lymphoid hyperplasia* 1/3 33 2/6 33 2/6 33 1/3 33
tracheobronchial lymph node
lymphadenitis, necrotizing 2/3 66 2/6 33 4/6 66 1/2 50
lymphoid depletion 2/3 66 3/6 50 3/6 50 0 0
lymphoid hyperplasia* 0 0 1/6 16 1/6 16 1/2 50
discrete foci of necrosis
/inflammation * 0 0 0 0 0 0 1/2 50
*=lesion seen in survivors.
doi:10.1371/journal.pone.0012880.t002
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airways but without regard to particle size and the physiological
deposition that occurs during the process of inhalation. Fibrino-
necrotic bronchopneumonia was described in animals that
received 10
7 pfu MPXV by i.t. inoculation, as was also the case
in animals infected by the aerosol route in this study as well as the
study by Zaucha and colleagues [25,34]. Intratracheal MPXV
infection with a comparable dose of virus to that used in this study
(10
6 PFU) resulted in a strikingly similar curve for viremia to that
seen in this study, with a large peak followed by a smaller peak at
approximately 22 days post exposure [34]. However, the timing of
the first peak was delayed by 5 days in i.t. exposed macaques
compared to aerosol infection, and the amount of virus detected
by qPCR was approximately 100-fold lower. This suggests that
local replication is more pronounced after aerosol delivery
compared to the i.t. route. Taken together, i.t. inoculation is
therefore not a substitute for the aerosol route of infection.
Human MPXV infection has a mortality ranging from 1.5% to
10% according to epidemiologic data, and is clinically indistinguish-
able from human smallpox except for a greater frequency of
lymphadenopathy [3,35,36]. Likewise, a 1961 study reported similar
diseasesafteraerosolinfection of cynomolgusmacaqueswith MPXV
compared to several VARV strains [37]. While MPXV is thought to
have a lower potential for human-to-human transmission than
VARV, it is currently the most troublesome orthopoxvirus for
humans, with sporadic outbreaks occurring most commonly in the
African Congo [35]. An outbreak of human monkeypox occurred in
the Midwestern US in 2003 after contact with prairie dogs infected
with a West African strain of MPXV [38]. MPXV-infected humans
had a longer incubation and shorter fever duration than the
macaques in this study, which may be due in part to a presumed
lower dose of a natural environmental exposure or differences in
virulence between the West African strain causing the US outbreak
and the Central African strain used for this study [17,39].
Hematology data indicated that WBC levels were significantly
increased from the baseline levels by day 4 post-exposure
(P=0.0013), with the WBC levels in some dosage groups
increasing above the normal range by day 10. The increased
neutrophils and decreased lymphocytes - although not true
neutrophilia and lymphopenia, since the values were within
reference ranges - would be consistent with an inflammatory
leukogram. Similarly, leukocytosis was observed in 45% of human
monkeypox cases [38]. Thrombocytopenia was seen in 35% of
human patients and significant decreases in platelet levels also
occurred on day 6 post-exposure in macaques. Histologic
evaluation of bone marrow did not reveal significant pathology;
thus, the mechanism of decreased platelets was unlikely due to
decreased production but more likely due to increased consump-
tion or removal due to viral infection.
In contrast to the human cases that had low BUN levels (61%),
MPXV exposed macaques had normal BUN indicating that
decreased production of urea or reduced availability of ammonia
for urea synthesis tends to occur in humans but may not occur in
MPXV infected macaques [38]. The animals in this study had no
pathologic abnormalities in the kidneys despite the persistence of
virus in the kidneys of animals surviving infection. Macaques in
the 1610
5 PFU, 4610
5 PFU, and 1610
6 PFU groups had
significantly elevated AST at day 10 post-exposure compared to
day -1 (P=0.002). Likewise, high transaminase levels were
detected in 50% of MPXV infected humans. Although AST levels
in MPXV infected macaques were within the normal range, the
levels were elevated compared to baseline levels.
LDH is a protein that aids in the removal of lactate from tissues.
Lactate is the end product when anaerobic glycolysis occurs in low
oxygen conditions. Increased LDH in MPX infection indicates
increased lactate and therefore decreased oxygen in the body.
Since aerosolized MPX infection affects the lungs, this is a possible
cause of elevated LDH levels. Additionally, because LDH lacks
tissue specificity and the major sources of high serum LDH activity
include muscle, liver, and erythrocytes, we cannot rule out these
sources as contributing factors. As observed in 50% of MPXV
infected humans diagnosed with hypoalbuminemia, significant
decreases in albumin levels were also seen in this study in each of
the dosage groups by day 6 post-exposure (P=0.0056). Hypopro-
teinemia and hypoalbuminemia likely resulted from anorexia
which may have been the consequence of lesions within the mouth
and esophagus. Thus, there are a number of similarities between
monkeypox disease in humans and aerosol exposed macaques.
The pathologic findings in this study are similar to those
reported by Zaucha et al. [25]. In animals with acute disease,
fibrinonecrotic bronchopneumonia was the most distinctive lesion
Figure 6. Pathology and presence of MPXV antigen in lung
tissue. Figures A–D are histological sections of lung tissues from
cynomolgus macaques infected via aerosolized MPXV. Positive immu-
noreactivity for orthopoxvirus antigen, shown as brown staining, is
associated with necrotizing lesions primarily concentrated around
bronchi and bronchioles. [Immunoperoxidase method using rabbit
polyclonal antibody to vaccinia virus; original magnification 640
(Figure 6A) or 620 (Figure 6 B, C, D)]. A)4 610
4 PFU (day 10 post-
exposure). B)1 610
5 PFU (day 8 post-exposure). C)4 610
5 PFU (day 11
post-exposure). D)1 610
6 PFU (day 9 post-exposure). E)P e r c e n t
immunoreactivity in the lungs of non-survivors by dosage group,
measured by digital microscopy image analysis.
doi:10.1371/journal.pone.0012880.g006
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foci of necrosis and inflammation appeared to be centered on large
airways. Other lesions in animals with acute disease included
necrotizing lesions in the skin, mucosal surfaces, lymphoid tissues,
and gonads. Cutaneous lesions ranged from very few in some
animals to too numerous to count in others. Additional lesions
seen in this study, albeit infrequently, were necrotizing lesions in
the prostate gland, uterus, skeletal muscle, and urinary bladder.
Hepatic lesions were not observed in our study, whereas Zaucha
et al. described disseminated hepatitis in 13% of MPXV infected
animals.
Generally, a dose of 10
6 pfu MPXV given by aerosol to
cynomolgus macaques is uniformly lethal and would be an
appropriate dose for testing of orthopoxvirus countermeasures
(data not shown). However, in this report, one of three animals
survived challenge at this dose, possibly due to individual
differences in the host immune response. Future studies should
be done to determine which primate host responses are amenable
to survival following aerosol exposure of MPXV.
Interestingly, the average weight of the survivors was 20%
heavier than that of the non-survivors. Macaques were between 4
and 6 years old, therefore age differences were not likely a factor in
survival. Of the five animals that survived, four were male,
indicating that males, which tend to be heavier, may be more
resistant to MPXV. Increased survival in male macaques could be
due either to gender or heavier weight. Among humans,
correlations of MPXV disease severity with weight, gender, or
age have not been made, although pediatric patients were more
likely than adults to be admitted into an intensive care unit in the
2003 US outbreak [38].
Unlike other animal models of orthopoxvirus infection, the
model presented here utilizes the respiratory route which is the
natural route of transmission for human VARV infections and a
secondary route for human MPXV infections. We have demon-
strated that aerosol infection of cynomolgus macaques with
MPXV has a number of parallels to human monkeypox and
smallpox diseases. Therefore, an aerosol infection model in NHPs
is important for understanding orthopoxvirus pathogenesis as well
as for future evaluation of novel vaccine and therapeutic
candidates.
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